Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease - Burmester, G R; Panaccione, R; Gordon, K B (Ann Rheum Dis, 2013)
et al.